Table 3:
Identified causes of treatment-related mortality
| All cancers (n=3569) | Haematological malignancy (n=2798) | CNS solid tumour (n=50) | Non-CNS solid tumour (n=199) | |
|---|---|---|---|---|
| Total number of patients* | 68351 | 51186 | 6240 | 10785 |
| Sepsis or infection | 2560 (71·7%) | 2069 (73·9%) | 28 (56·0%) | 101 (50·8%) |
| Haemorrhage | 379 (10·6%) | 306 (10·9%) | 4 (8·0%) | 4 (2·0%) |
| Metabolic causes (tumour lysis syndrome) | 174 (4·9%) | 162 (5·8%) | 0 | 1 (0·5%) |
| Disseminated intravascular coagulation | 13 (0·4%) | 12 (0·4%) | 0 | 0 |
| Surgical complications | 51 (1·4%) | 2 (0·1%) | 7 (14·0%) | 25 (12·6%) |
| Neurological complications (encephalopathy or raised intracranial pressure) | 26 (0·7%) | 21 (0·8%) | 1 (2·0%) | 1 (0·5%) |
| Seizures | 4 (0·1%) | 2 (0·1%) | 2 (4·0%) | 0 |
| Cardiac failure | 43 (1·2%) | 17 (0·6%) | 0 | 15 (7·5%) |
| Respiratory failure | 99 (2·8%) | 80 (2·9%) | 0 | 6 (3·0%) |
| Superior vena cava syndrome | 5 (0·1%) | 5 (0·2%) | 0 | 0 |
| Hyperleukocytosis | 8 (0·2%) | 8 (0·3%) | 0 | 0 |
| Other chemotherapy toxicity | 90 (2·5%) | 32 (1·1%) | 6 (12·0%) | 33 (16·6%) |
| Other organ failure | 98 (2·7%) | 72 (2·6%) | 1 (2·0%) | 6 (3·0%) |
| Other | 19 (0·5%) | 10 (0·4%) | 1 (2·0%) | 7 (3·5%) |
Data are n (%), unless otherwise stated.
*
Due to the inclusion of studies with multiple diagnoses across several diagnostic categories, the total number of patients with any malignancy is greater than the sum of patients in the given categories.